Lexeo Therapeutics, Inc. Common Stock (LXEO)
USD 6.36
(-8.62%)
USD 6.36
(-8.62%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | - | 654 Thousand | 1.65 Million | 518.47 Thousand |
| Cost of Revenue | 1.84 Million | 1.14 Million | 13.4 Thousand | - |
| Gross Profit | -1.84 Million | -491 Thousand | 1.64 Million | 518.47 Thousand |
| Operating Expenses | 68.51 Million | 61.16 Million | 52.29 Million | 5.1 Million |
| Selling, General and Administrative Expenses | 13.54 Million | 12 Million | 7.17 Million | 787.49 Thousand |
| Research and Development Expenses | 53.13 Million | 49.16 Million | 45.12 Million | 4.31 Million |
| Other Expenses | - | -2000.00 | -155.00 | 4241.00 |
| Cost and Expenses | 68.51 Million | 61.16 Million | 52.29 Million | 5.1 Million |
| Operating Income | -68.51 Million | -60.5 Million | -50.63 Million | -4.58 Million |
| Interest Expense | 205 Thousand | 91 Thousand | - | 147.15 Thousand |
| Income Tax Expense | - | 89 Thousand | -155.00 | 147.15 Thousand |
| Earnings before Tax | -66.39 Million | -59.27 Million | -50.62 Million | -5.15 Million |
| Net Income | -66.39 Million | -59.27 Million | -50.62 Million | -5.15 Million |
| Earnings Per Share Basic | -2.49 | -2.40 | -2.05 | -0.21 |
| Earnings Per Share Diluted | -2.49 | -2.40 | -2.05 | -0.21 |
| Weighted Average Shares Outstanding | 26.64 Million | 24.66 Million | 24.66 Million | 24.66 Million |
| Weighted Average Shares Outstanding (Diluted) | 26.64 Million | 24.66 Million | 24.66 Million | 24.66 Million |
| Gross Margin | - | -0.75 | 0.99 | 1.00 |
| EBIT Margin | - | -88.75 | -30.54 | -8.84 |
| Profit Margin | - | -90.64 | -30.55 | -9.94 |
| EBITDA | -66.67 Million | -58.04 Million | -50.62 Million | -4.58 Million |
| Earnings Before Tax Margin | - | -92.52 | -30.56 | -8.85 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 496 Thousand | 476 Thousand | 1.84 Million | 490 Thousand | 460 Thousand | 446.06 Thousand |
| Gross Profit | -496 Thousand | -476 Thousand | -1.84 Million | -490 Thousand | -460 Thousand | -446.06 Thousand |
| Operating Expenses | 23.05 Million | 23.29 Million | 66.67 Million | 14.97 Million | 20.27 Million | 13.97 Million |
| Selling, General and Administrative Expenses | 6.49 Million | 7.54 Million | - | 6.76 Million | 3.02 Million | 2.73 Million |
| Research and Development Expenses | 16.55 Million | 15.74 Million | - | 8.21 Million | 17.24 Million | 11.23 Million |
| Other Expenses | -1000.00 | -5000.00 | - | -7000.00 | 1000.00 | -3000.00 |
| Cost and Expenses | 23.55 Million | 23.29 Million | 68.51 Million | 14.97 Million | 20.27 Million | 13.97 Million |
| Operating Income | -23.55 Million | -23.29 Million | -68.51 Million | -14.97 Million | -20.27 Million | -13.97 Million |
| Interest Expense | 35 Thousand | 37 Thousand | 205 Thousand | 50 Thousand | 52 Thousand | 53 Thousand |
| Income Tax Expense | - | 32 Thousand | -1.00 | 43 Thousand | 53 Thousand | -537 Thousand |
| Earnings before Tax | -21.23 Million | -21.68 Million | -66.39 Million | -14.18 Million | -20.1 Million | -13.44 Million |
| Net Income | -21.23 Million | -21.68 Million | -66.39 Million | -14.18 Million | -20.1 Million | -13.44 Million |
| Earnings Per Share Basic | -0.64 | -0.77 | - | -0.53 | -0.80 | -0.54 |
| Earnings Per Share Diluted | -0.64 | -0.77 | - | -0.53 | -0.80 | -0.54 |
| Weighted Average Shares Outstanding | 33 Million | 27.97 Million | 26.64 Million | 26.57 Million | 25.16 Million | 24.66 Million |
| Weighted Average Shares Outstanding (Diluted) | 33 Million | 27.97 Million | 26.64 Million | 26.57 Million | 25.16 Million | 24.66 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -23.05 Million | -21.16 Million | - | -13.38 Million | -19.32 Million | -13.38 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
6049
ENTEL
115390
GHY
600726
600779